MX347654B - Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. - Google Patents
Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion.Info
- Publication number
- MX347654B MX347654B MX2015005873A MX2015005873A MX347654B MX 347654 B MX347654 B MX 347654B MX 2015005873 A MX2015005873 A MX 2015005873A MX 2015005873 A MX2015005873 A MX 2015005873A MX 347654 B MX347654 B MX 347654B
- Authority
- MX
- Mexico
- Prior art keywords
- expression
- evolution
- antibody
- simultaneous
- protein performance
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000005457 optimization Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Ecology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un método de desarrollo y expresión de un anticuerpo en un hospedero de producción de células eurcariotas; el método caracterizado porque comprende: a. seleccionar un anticuerpo molde; b .desarrollar el anticuerpo molde para permitir la producción de una serie de anticuerpos mutantes en un hospedero de producción de células eurcariotas; c. examinar los anticuerpos mutantes para al menos una propiedad, característica o actividad predeterminada; d. seleccionar un anticuerpo sobre-mutante de la serie de anticuerpos mutantes con base en la optimización de la al menos una propiedad, característica o actividad predeterminada en comparación con la misma propiedad, característica o actividad predeterminada del anticuerpo molde; y e. expresar el anticuerpo sobre-mutante en el mismo hospedero de producción de células eucariotas con el paso (b) para cualquier escala comercial.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27116809P | 2009-07-17 | 2009-07-17 | |
| PCT/US2010/042302 WO2011009058A2 (en) | 2009-07-17 | 2010-07-16 | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX347654B true MX347654B (es) | 2017-05-05 |
Family
ID=43450243
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005873A MX347654B (es) | 2009-07-17 | 2010-07-16 | Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. |
| MX2017000699A MX392642B (es) | 2009-07-17 | 2010-07-16 | Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. |
| MX2012000803A MX2012000803A (es) | 2009-07-17 | 2010-07-16 | Selección y desarrollo integrados simultáneos del desempeño y la expresión de proteínas/anticuerpos en hospederos de producción. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000699A MX392642B (es) | 2009-07-17 | 2010-07-16 | Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. |
| MX2012000803A MX2012000803A (es) | 2009-07-17 | 2010-07-16 | Selección y desarrollo integrados simultáneos del desempeño y la expresión de proteínas/anticuerpos en hospederos de producción. |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US8859467B2 (es) |
| EP (6) | EP3042957B1 (es) |
| JP (3) | JP6193570B2 (es) |
| KR (5) | KR20220002712A (es) |
| CN (2) | CN102625848A (es) |
| AU (5) | AU2010273974B2 (es) |
| BR (2) | BR122015012748A2 (es) |
| CA (2) | CA3034484A1 (es) |
| DK (5) | DK3636759T3 (es) |
| ES (3) | ES2581318T3 (es) |
| HU (1) | HUE029328T2 (es) |
| IN (1) | IN2012DN00737A (es) |
| MX (3) | MX347654B (es) |
| MY (2) | MY160472A (es) |
| PL (2) | PL2907873T3 (es) |
| PT (1) | PT3042957T (es) |
| SG (3) | SG177687A1 (es) |
| WO (1) | WO2011009058A2 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3636759T3 (da) | 2009-07-17 | 2023-10-23 | Bioatla Inc | Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelse og ekspression hos produktionsværter |
| WO2011109726A2 (en) * | 2010-03-05 | 2011-09-09 | Bioatla Llc | Homologous multi-specific antibodies |
| AU2015242961B2 (en) * | 2010-07-16 | 2017-03-02 | Bioatla, Llc | Novel methods of protein evolution |
| ES2966088T3 (es) * | 2010-07-16 | 2024-04-18 | Bioatla Inc | Nuevos métodos de evolución de proteínas |
| KR20130096731A (ko) | 2010-09-08 | 2013-08-30 | 할로자임, 아이엔씨 | 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법 |
| WO2013067322A1 (en) * | 2011-11-03 | 2013-05-10 | Stc Biologics, Inc. | Method for determination of pharmacological properties of recombinant proteins |
| WO2014179363A1 (en) | 2013-04-29 | 2014-11-06 | Adimab, Llc | Polyspecificity reagents, methods for their preparation and use |
| EP3092491B1 (en) | 2014-01-07 | 2018-10-31 | Bioatla, LLC | Proteins targeting orthologs |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| ES2913205T3 (es) * | 2014-05-13 | 2022-06-01 | Bioatla Inc | Proteínas biológicas activas condicionalmente |
| WO2016004242A1 (en) * | 2014-07-01 | 2016-01-07 | Stc Biologics, Inc. | A method for development of recombinant proteins with fingerprint like similarity to the reference product |
| ES3034398T3 (en) * | 2014-08-28 | 2025-08-18 | Bioatla Inc | Conditionally active chimeric antigen receptors for modified t-cells |
| CA2959786A1 (en) | 2014-09-03 | 2016-03-10 | Bioatla, Llc | Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts |
| KR102790523B1 (ko) | 2015-02-24 | 2025-04-02 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 생체 단백질 |
| CN116987187A (zh) * | 2015-09-23 | 2023-11-03 | 豪夫迈·罗氏有限公司 | 抗-vegf抗体的优化的变体 |
| RU2735023C9 (ru) | 2015-11-02 | 2021-06-18 | Биоатла, Ллс | Условно активные полипептиды |
| ES2930255T3 (es) | 2016-05-13 | 2022-12-09 | Bioatla Inc | Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos |
| IL322943A (en) | 2017-07-11 | 2025-10-01 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and their use |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| CN113924118A (zh) | 2019-04-18 | 2022-01-11 | 百时美施贵宝公司 | 在低ph下具有增强的结合特异性的伊匹单抗变体 |
| US20240124889A1 (en) | 2019-05-07 | 2024-04-18 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN111048154B (zh) * | 2019-12-10 | 2023-06-06 | 上海药明生物技术有限公司 | 一种抗体表位作图的方法 |
| CN111462815B (zh) * | 2020-03-27 | 2023-05-02 | 上海祥耀生物科技有限责任公司 | 一种抗体库的构建方法及装置 |
| US11506060B1 (en) * | 2021-07-15 | 2022-11-22 | Honeywell International Inc. | Radial turbine rotor for gas turbine engine |
| US20250223376A1 (en) | 2021-09-20 | 2025-07-10 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| AU2023320453A1 (en) | 2022-08-03 | 2025-02-06 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4957858A (en) | 1986-04-16 | 1990-09-18 | The Salk Instute For Biological Studies | Replicative RNA reporter systems |
| US4883750A (en) | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| AU622104B2 (en) | 1987-03-11 | 1992-04-02 | Sangtec Molecular Diagnostics Ab | Method of assaying of nucleic acids, a reagent combination and kit therefore |
| CA1323293C (en) | 1987-12-11 | 1993-10-19 | Keith C. Backman | Assay using template-dependent nucleic acid probe reorganization |
| JP2846018B2 (ja) | 1988-01-21 | 1999-01-13 | ジェネンテク，インコーポレイテッド | 核酸配列の増幅および検出 |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| AU623642B2 (en) | 1988-03-24 | 1992-05-21 | University Of Iowa Research Foundation, The | Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| PT670898E (pt) | 1992-11-24 | 2004-02-27 | Searle & Co | Polipeptidos de multiplas mutacoes de interleucina-3 (il-3) |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
| US20030219752A1 (en) * | 1995-12-07 | 2003-11-27 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US8137906B2 (en) | 1999-06-07 | 2012-03-20 | Sloning Biotechnology Gmbh | Method for the synthesis of DNA fragments |
| US7033781B1 (en) | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
| BR0207267A (pt) | 2001-02-19 | 2004-02-10 | Merck Patent Gmbh | Proteìnas artificiais com imunogenicidade reduzida |
| US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
| JP2004532038A (ja) * | 2001-05-17 | 2004-10-21 | ディヴァーサ コーポレイション | 新規抗原結合分子の治療、診断、予防、酵素、産業ならびに農業各分野への応用とそのための新規抗原結合分子の作製とスクリーニングの方法 |
| US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| WO2005003345A2 (en) * | 2003-06-27 | 2005-01-13 | R. Crea & Co. | Look-through mutagenesis |
| GB0520169D0 (en) * | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
| KR20080073293A (ko) | 2005-10-14 | 2008-08-08 | 메디뮨 엘엘씨 | 항체 라이브러리의 세포 디스플레이 |
| EP2617827A1 (en) * | 2007-03-26 | 2013-07-24 | Celexion, LLC | Method for displaying engineered proteins on a cell surface |
| WO2009059235A2 (en) | 2007-11-01 | 2009-05-07 | Facet Biotech Corporation | Immunoglobulin display vectors |
| US9249408B2 (en) | 2007-11-02 | 2016-02-02 | The Scripps Research Institute | Directed evolution using proteins comprising unnatural amino acids |
| US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
| DK3636759T3 (da) | 2009-07-17 | 2023-10-23 | Bioatla Inc | Samtidig, integreret udvælgelse og udvikling af antistof/protein-ydelse og ekspression hos produktionsværter |
| FR2957821B1 (fr) | 2010-03-24 | 2014-08-29 | Inst Francais Du Petrole | Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives |
-
2010
- 2010-07-16 DK DK19210622.7T patent/DK3636759T3/da active
- 2010-07-16 EP EP16157965.1A patent/EP3042957B1/en active Active
- 2010-07-16 DK DK18183032.4T patent/DK3406717T3/da active
- 2010-07-16 MY MYPI2012000207A patent/MY160472A/en unknown
- 2010-07-16 DK DK15156820.1T patent/DK2907873T3/en active
- 2010-07-16 EP EP19210622.7A patent/EP3636759B1/en active Active
- 2010-07-16 CN CN2010800388394A patent/CN102625848A/zh active Pending
- 2010-07-16 BR BR122015012748-3A patent/BR122015012748A2/pt not_active Application Discontinuation
- 2010-07-16 ES ES15156820.1T patent/ES2581318T3/es active Active
- 2010-07-16 KR KR1020217042385A patent/KR20220002712A/ko not_active Ceased
- 2010-07-16 DK DK16157965.1T patent/DK3042957T3/en active
- 2010-07-16 KR KR1020197004078A patent/KR20190017070A/ko not_active Ceased
- 2010-07-16 CN CN201611220313.3A patent/CN107090031A/zh active Pending
- 2010-07-16 MX MX2015005873A patent/MX347654B/es unknown
- 2010-07-16 EP EP16196481.2A patent/EP3156485B1/en active Active
- 2010-07-16 HU HUE15156820A patent/HUE029328T2/en unknown
- 2010-07-16 ES ES16157965.1T patent/ES2652340T3/es active Active
- 2010-07-16 DK DK16196481.2T patent/DK3156485T3/en active
- 2010-07-16 SG SG2012003356A patent/SG177687A1/en unknown
- 2010-07-16 KR KR1020127003948A patent/KR101823872B1/ko active Active
- 2010-07-16 ES ES16196481T patent/ES2701931T3/es active Active
- 2010-07-16 EP EP18183032.4A patent/EP3406717B1/en active Active
- 2010-07-16 SG SG10201700096VA patent/SG10201700096VA/en unknown
- 2010-07-16 MX MX2017000699A patent/MX392642B/es unknown
- 2010-07-16 PL PL15156820.1T patent/PL2907873T3/pl unknown
- 2010-07-16 US US13/384,362 patent/US8859467B2/en active Active
- 2010-07-16 PL PL16157965T patent/PL3042957T3/pl unknown
- 2010-07-16 AU AU2010273974A patent/AU2010273974B2/en active Active
- 2010-07-16 SG SG10201505075TA patent/SG10201505075TA/en unknown
- 2010-07-16 MX MX2012000803A patent/MX2012000803A/es active IP Right Grant
- 2010-07-16 KR KR1020217002264A patent/KR20210013294A/ko not_active Ceased
- 2010-07-16 KR KR1020187002028A patent/KR20180010347A/ko not_active Ceased
- 2010-07-16 BR BR112012001171-5A patent/BR112012001171B1/pt active IP Right Grant
- 2010-07-16 JP JP2012520813A patent/JP6193570B2/ja active Active
- 2010-07-16 CA CA3034484A patent/CA3034484A1/en active Pending
- 2010-07-16 EP EP15156820.1A patent/EP2907873B1/en active Active
- 2010-07-16 CA CA2768247A patent/CA2768247C/en active Active
- 2010-07-16 MY MYPI2015002586A patent/MY173037A/en unknown
- 2010-07-16 PT PT161579651T patent/PT3042957T/pt unknown
- 2010-07-16 WO PCT/US2010/042302 patent/WO2011009058A2/en not_active Ceased
- 2010-07-16 EP EP10800618.0A patent/EP2454376B1/en active Active
-
2011
- 2011-11-17 US US13/298,559 patent/US10106788B2/en active Active
-
2012
- 2012-01-25 IN IN737DEN2012 patent/IN2012DN00737A/en unknown
-
2014
- 2014-09-09 US US14/481,564 patent/US10047357B2/en active Active
-
2015
- 2015-05-06 JP JP2015094521A patent/JP6193913B2/ja active Active
- 2015-10-16 AU AU2015243076A patent/AU2015243076B2/en active Active
-
2017
- 2017-05-15 AU AU2017203243A patent/AU2017203243B2/en active Active
- 2017-06-02 JP JP2017109593A patent/JP6681131B2/ja active Active
-
2018
- 2018-08-31 US US16/118,673 patent/US10920216B2/en active Active
-
2019
- 2019-05-31 AU AU2019203813A patent/AU2019203813B2/en active Active
-
2021
- 2021-01-27 US US17/159,936 patent/US11976381B2/en active Active
- 2021-05-19 AU AU2021203220A patent/AU2021203220B2/en active Active
-
2024
- 2024-03-21 US US18/612,054 patent/US20240263354A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX347654B (es) | Seleccion y desarrollo integrados simultaneos del desempeño y la expresion de proteinas/anticuerpos en hospederos de produccion. | |
| TN2011000433A1 (en) | Alpha -4-beta-7heterodimer specific antagonist antibody | |
| EP4477668A3 (en) | Heterodimeric antibody fc-containing proteins and methods for production thereof | |
| MX2009012747A (es) | Produccion de proteina recombinante en celulas ebx de aves. | |
| EA201301180A1 (ru) | Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой | |
| MY176026A (en) | Methods and composions comprising purified recombinant polypeptides | |
| EP2534257A4 (en) | METHOD OF IDENTIFYING AND ISOLATING CELLS FOR THE EXPRESSION OF POLYPEPTIDES | |
| NO20083127L (no) | Fremgangsmater og preparater for malretting av polyubiquitin | |
| WO2012054929A3 (en) | Use of human serum albumin to decrease antigenicity of therapeutic proteins | |
| MX2013011706A (es) | Proteinas novedosas de enlace a antigeno. | |
| GB201003701D0 (en) | System for the expression of a protein | |
| WO2012068317A3 (en) | Methods for producing recombinant proteins | |
| MX360543B (es) | Anticuerpos st-2 humanos solubles y ensayos. | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| TN2014000120A1 (en) | Cd27l antigen binding proteins | |
| TN2010000616A1 (en) | Human cytomegalovirus neutralising antibodies and use thereof | |
| MY150400A (en) | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof | |
| EP2516624A4 (en) | CELL LINE 3M | |
| MX2015012168A (es) | Expansión de celulas madre adultas in vitro. | |
| WO2008081031A3 (en) | Methods of increasing the production yield of a secreted antibody in a filamentous fungus by overexpression of the chaperone bip | |
| CL2014003569A1 (es) | Método de producción de iduronato-2-sulfatasa (i2s), que comprende cultivar células de mamíferos que coexpresan i2s recombinante y una enzima generadora formilglicina (fge); preparación de proteína i2s; composición farmacéutica; y uso para tratar síndrome de hunter. | |
| WO2011128820A3 (en) | Methods for the analysis of breast cancer disorders | |
| AU2016219622A1 (en) | Heterodimeric antibody FC-containing proteins and methods for production thereof | |
| AU2011207257A8 (en) | Immunoregulation by anti-ILT5 antibodies and ILT5-binding antibody fragments | |
| UA69272U (ru) | Способ выделения и очистки igm человека |